1 published article · Updated continuously
12 trials tracked for graft rejection: 7 in phase 3 or 4 and 1 with published results. The most-cited published study has 6 citations.
Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Management of graft rejection involves several pharmacological interventions. Tacrolimus has been evaluated for maintenance immunosuppression, showing a patient survival rate with a functioning graft of approximately 92% to 96% (p=0.26) and a rejection-free survival rate ranging from 80.1% to 86.4% (p=0.48) 2. In studies comparing cyclosporine and tacrolimus, significant differences were observed in serum creatinine levels at various intervals post-randomization (p=0.009), though the number of participants experiencing acute rejection did not reach statistical significance (p=0.206) 5.
Everolimus has been utilized as an intervention with established outcomes regarding graft stability. In one study, 33.6% to 35.1% of participants experienced composite efficacy failure at 12 months, while the rate of graft loss, death, or loss to follow-up was approximately 8.9% to 11.9% 6. A non-inferiority analysis for everolimus showed a significant result (p=0.014) regarding composite efficacy endpoints and a significant finding (p=0.001) for the incidence of graft loss, death, or loss to follow-up at 12 months 7.
Additional interventions include Alemtuzumab 1 and Azithromycin. The use of Azithromycin was associated with statistically significant lower rates of both acute rejection (p<0.05) and infection (p<0.05) compared to the control group 4.
AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
